In this edition of AI Prognosis: Quirky medical data tripping up sepsis algorithms, AI scribes for patients, and some AI biotech news.
Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.
In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.
“The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.
It’s time to rethink and redesign how patients enter the health care system altogether, writes emergency physician Iyesatta Massaquoi Emeli.
Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-consumer telehealth businesses.
Two years after General Catalyst said it was buying Ohio safety-net hospital Summa Health, executives shed light on how the “transformation” is going.
In this edition of STAT Health Tech: A new wave of blood pressure monitoring wearables, Stanford asking patients about AI, and more.
Wearables with unvalidated blood pressure measuring tech are flooding the market after the FDA relaxed oversight of wellness devices.
In this edition of AI Prognosis, Brittany Trang takes a look at patients' role in how Stanford Health Care adopts AI tools, and more health AI news.
Stanford Health Care started asking patients about new AI tools before they are implemented. Here's what patients are telling them.
In this edition of STAT Health Tech: Early data from a Utah pilot using AI to renew prescriptions, Oura files to go public, and more.
Congressional Democrats are mounting a fresh effort to end a Medicare experiment to use AI to approve or deny care.
OpenEvidence CTO Zachary Ziegler said, at the STAT Breakthrough Summit West, that the company is looking beyond physician users.
In this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.
In this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.
In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.
A state-by-state approach to clinical AI won’t work. Here’s a framework that can.
Roche has signed a deal to acquire PathAI to speed up its use of artificial intelligence to help pathologists diagnose diseases.
“Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study found
In this edition of STAT Health Tech: A health policy blueprint from OpenAI, CGM updates from Dexcom, and push back against whole body scans.
Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.
In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
In this edition of STAT Health Tech: A high-profile study on AI's diagnostic capabilities, role of telehealth in abortion access, and an Epic lawsuit.
In recent years, at-home recovery tech has gained significant attention. It uses non-invasive red light therapy, which has been studied for its potential to stimulate biological processes, helping support pain relief and muscle recovery. Belts stand out from other red light therapy devices for their sheer convenience, providing hands-free sessions that may help manage soreness [...]
The post…
It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
On Thursday, researchers published in Science the results of a study that tested an OpenAI model on diagnostic and clinical reasoning tasks.
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
Page 1
Older →